AbolerIS Pharma

AbolerIS Pharma develops potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset. The company is advancing a novel class of antibodies targeting CD45RC, with its lead program ABO21009 in Phase 1, designed to treat rheumatoid arthritis, inflammatory bowel disease, and organ transplantation rejection.